LAG3 and glioblastoma: The reduction of LAG-3 expression on CD3+ cells was found to be significantly lower in relapses only in the marginal area (Figure 3B, M: 20.46% at diagnosis, 9.22% at relapse, p = 0.04; C: 17.13% at diagnosis, 9.03% at relapse, ns); a reduced expression of LAG-3 was on CD8+ T cells of the central area of relapsing GBM (Figure 3B, 19.65% in newly diagnosed GBM, 8.93% in recurrences, p = 0.036), while the highest reduction of LAG-3 expression was observed on CD4+ T cells present in the marginal zone (Figure 3B, 20.32% at diagnosis, 7.95% at relapse, p = 0.011).